AI Automated Translation.

Font Size

Share

Joa Pharmaceutical posts operating profit in Q3 on standalone basis, signaling visible earnings improvement

Joa Pharmaceutical posts operating profit in Q3 on standalone basis, signaling visible earnings improvement

Exterior view of Joa Pharmaceutical's Haman plant /Photo=Joa Pharmaceutical
Exterior view of Joa Pharmaceutical's Haman plant /Photo=Joa Pharmaceutical

Joa Pharmaceutical's third-quarter operating profit on a standalone basis turned positive year-on-year. However, the company continued to post an operating loss on a consolidated basis.

According to the Financial Supervisory Service's electronic disclosure system on the 17th, Joa Pharmaceutical's Q3 operating profit on a standalone basis was 145.75 million won, marking a shift from a loss in the same period last year to a profit. The company's net income for the third quarter also turned positive at 11.53 million won. Revenue declined by 8.5% to 13.6 billion won.

On a consolidated basis, the Q3 operating loss persisted at 251.19 million won. The net loss for the period was 472.47 million won, indicating that the net income deficit also continued. Third-quarter revenue fell by 10.7% year-on-year to 13.8 billion won.

Joa Pharmaceutical's cumulative consolidated revenue for the first three quarters of this year reached 43.68563 billion won, a 0.4% increase from the same period last year. The cumulative operating loss was 1.39409 billion won. Over the same period, cumulative standalone revenue rose by 1.5% to 43.0048 billion won, while the cumulative operating loss stood at 744.24 million won.

Joa Pharmaceutical explained that it is focusing on expanding exports and enhancing the competitiveness of its key products while maintaining the revenue base of its existing businesses.

Cumulative export sales for the first three quarters totaled 6.04724 billion won. This figure exceeds last year's annual export total of 5.83974 billion won, surpassing the previous year's full-year performance within just three months this year.

Recently, Joa Pharmaceutical signed an export contract for its iron supplement "New Hem Forte Syrup" with Kinmed Pharma, a pharmaceutical manufacturing and distribution company in the Democratic Republic of Congo. The company also signed a memorandum of understanding (MOU) with Japan's Blue Opener and is continuing to collaborate on entering major local distribution channels, including Don Quijote. It is also advancing its dermocosmetics (skin science cosmetics) business as a new growth driver.

In the general over-the-counter drug segment, the relaunch of its flagship product "Gareo Liquid" has yielded notable results. Since its relaunch in August, approximately 500,000 units of Gareo have been supplied to pharmacies. Joa Pharmaceutical plans to develop a soft capsule formulation of Gareo to expand its product lineup and strengthen its position in the digestive aid market.

A company official said, "Efforts to enhance business competitiveness are translating into visible results," adding, "We will identify new growth drivers and boost the competitiveness of our core businesses to build a foundation for stable growth."

"This article was translated using AI and may differ slightly from the original."